MediWound Ltd. (MDWD)
| Market Cap | 199.45M |
| Revenue (ttm) | 19.72M |
| Net Income (ttm) | -28.06M |
| Shares Out | 10.79M |
| EPS (ttm) | -2.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,704 |
| Open | 18.00 |
| Previous Close | 18.10 |
| Day's Range | 17.91 - 18.55 |
| 52-Week Range | 8.90 - 24.00 |
| Beta | 0.81 |
| Analysts | Strong Buy |
| Price Target | 25.00 (+35.25%) |
| Earnings Date | Nov 26, 2024 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other ha... [Read more]
Financial Performance
In 2023, MediWound's revenue was $18.69 million, a decrease of -29.48% compared to the previous year's $26.50 million. Losses were -$6.72 million, -65.73% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for MDWD stock is "Strong Buy" and the 12-month stock price forecast is $25.0.
News
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - ...
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC F...
MediWound Is A Healthy Investment
MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, ...
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective...
MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - ...
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ;...
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Remova...
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs)
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investmen...
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment Mölnlycke Health Care, a global leader in innovative wound care solutions, leads...
MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenso...
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024...
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing
MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript
MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 2024...
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients wi...
MediWound to Participate in Two Upcoming Investor Conferences
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today ...
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-su...
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go be...